New approaches to the treatment of rosacea on the basis pathogenesis factors and clinical forms

Abstract

Uncovering the molecular mechanisms of the rosacea pathogenesis and treatment are still of great importance. The review encompasses the modern knowledge of rosacea classification, characterization of the severity of the course of the subtypes, and pathogenesis features. Recent methods of rosacea treatment are presented, including the use of botulinum neuroprotein for the correction of the erythematous-telangiectatic subtype of the dermatosis.

The relevance of this problem is due to the chronic course of the disease and the peculiarity of the localization of rosacea manifestations that leads to a traumatic effect and often causes social exclusion of patients.

The rise of the rosacea incidences, along with other reasons like characteristics of the course of dermatosis, accompanied by frequent long-term relapses, is due to the resistance to generally accepted methods of drug therapy, often resulting in shortened clinical remission. All the factors lead to decreasing of patient’s life quality that require the search for effective therapy approaches. Among modern rosacea therapy, the application of botulinum neuroprotein is widely used; however, the clinical studies confirming the effectiveness of this technique are not presented enough.

Keywords

rosacea / pathogenesis / classification / treatment / botulinum neuroprotein

References

[1] Kubanova AA, Kubanov AA, Araviiskaia ER, Samcov AV. Federal clinical recommendation of rosacea. Dermatovenereology. Moscow: Business Express; 2015. Р. 528–541. (In Russ).

[2] Кубанова А.А., Кубанов А.А., Аравийская Е.Р., Самцов А.В. Федеральные клинические рекомендации. Дерматовенерология. Москва: Деловой экспресс, 2015. С. 528–541.

[3] Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019;80(6):1722–1729. doi: 10.1016/j.jaad.2018.08.049

[4] Alexis A.F., Callender V.D., Baldwin H.E., et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience // J Am Acad Dermatol. 2019. Vol. 80, N 6. Р. 1722–1729. doi: 10.1016/j.jaad.2018.08.049

[5] Tan J, Schöfer H, Araviiskaia E, et al.; RISE study group. Prevalence of rosacea in the general population of Germany and Russia: The RISE study. J Eur Acad Dermatol Venereol. 2016;30(3):428–434. doi: 10.1111/jdv.13556

[6] Tan J., Schöfer H., Araviiskaia E., et al. RISE study group. Prevalence of rosacea in the general population of Germany and Russia: The RISE study // J Eur Acad Dermatol Venereol. 2016. Vol. 30, N 3. Р. 428–434. doi: 10.1111/jdv.13556

[7] Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574. doi: 10.1080/19381980.2017.1361574

[8] Rainer B.M., Kang S., Chien A.L. Rosacea: Epidemiology, pathogenesis, and treatment // Dermatoendocrinol. 2017. Vol. 9, N 1. Р. e1361574. doi: 10.1080/19381980.2017.1361574

[9] Snarskaya E, Rusina T. Contemporary views of the pathogenesis and classification of rosacea. Vrach. 2019;30(3):17–21. (In Russ). doi: 10.29296/25877305-2019-03-03

[10] Снарская Е., Русина Т. Современные представления о патогенезе и классификации розацеа // Врач. 2019. Т. 30, N 3. С. 17–20. doi: 10.29296/25877305-2019-03-03

[11] Zhiltsova EE, Mezhevaya KV, Isakov SA. Modern aspects of the prevalence and clinic of rosacea. Attending Physician. 2019;(9):80–82. (In Russ). doi: 10.26295/OS.2019.45.15.017

[12] Жильцова Е.Е., Межевая К.В., Исаков С.А. Современные аспекты распространенности и клиники розацеа // Лечащий врач. 2019. № 9. С. 80–82. doi: 10.26295/OS.2019.45.15.017

[13] Snarskaya ES, Rusina TS. Modern concepts of erythematotelangiectatic rosacea pathogenesis and treatment. Russ J Skin Venereal Dis. 2021;24(4):367–374. (In Russ). doi: 10.17816/dv87993

[14] Снарская Е.С., Русина Т.С. Современные представления о патогенезе и лечении эритематозно-телеангиэктатического субтипа розацеа // Российский журнал кожных и венерических болезней. 2021. Т. 24, № 4. С. 367–374. doi: 10.17816/dv87993

[15] Wilkin J, Dahl M, Detmar M, et al. Standart classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002:46(4):584–587. doi: 10.1067/mjd.2002.120625

[16] Wilkin J., Dahl M., Detmar M., et al. Standart classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea // J Am Acad Dermatol. 2002. Vol. 46, N 4. Р. 584–587. doi: 10.1067/mjd.2002.120625

[17] Prokhorenkov VI, Mikhel DV, Guzey TN. Rosacea: Modern aspects of the etiology and pathogenesis. Clin Dermatol Venereol. 2015;(1):4–14. (In Russ). doi: 10.17116/klinderma201514-11

[18] Прохоренков В.И., Михель Д.И., Гузей Т.Н. Розацеа: современные аспекты этиологии и патогенеза // Клиническая дерматология и венерология 2015. № 1. С. 4–14. doi: 10.17116/klinderma201514-11

[19] Schaller M, Almeida LM, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269–1276. doi: 10.1111/bjd.18420

[20] Schaller M., Almeida L.M., Bewley A., et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus 2019 panel // Br J Dermatol. 2020. Vol. 182, N 5. Р. 1269–1276. doi: 10.1111/bjd.18420

[21] Samtsov AV. The evolution of ideas about rosacea. Opinion Leader. 2020;(39):53–58. (In Russ).

[22] Самцов А.В. Эволюция представлений о розацеа // Opinion Leader. 2020. № 39. С. 53–58.

[23] Ahn CS, Huang WW. Rosacea Pathogenesis. Dermatol Clin. 2018;36(2):81–86. doi: 10.1016/j.det.2017.11.001

[24] Ahn C.S., Huang W.W. Rosacea pathogenesis // Dermatol Clin. 2018. Vol. 36, N 2. Р. 81–86. doi: 10.1016/j.det.2017.11.001

[25] Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–980. doi: 10.1038/nm1616

[26] Yamasaki K., Di Nardo A., Bardan A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea // Nat Med. 2007. Vol. 13, N 8. Р. 975–980. doi: 10.1038/nm1616

[27] Slesarenko NA, Leonova MA, Bakulev AL, et al. Role of the Helicobacter pylori as a trigger factor in the development of rosacea and effect of its eradication on the course of dermatosis. Bulletin Dermatol Venereol. 2012;88(2):33–39. (In Russ). doi: 10.25208/vdv664

[28] Слесаренко Н.А., Леонова М.А., Бакулев А.Л., и др. Роль Helicobacter pylori как триггерного фактора в развитии розацеа и влияние ее эрадикации на течение дерматоза // Вестник дерматологии и венерологии. 2012. Т. 88, № 2. С. 33–39. doi: 10.25208/vdv664

[29] Kubanova AA, Mahakova YB. Rosacea: Prevalence, pathogenesis, particular features of clinical manifestations. Bulletin Dermatol Venereol. 2015;(3):36–45. (In Russ).

[30] Кубанова А.А., Махакова Ю.Б. Розацеа: распространенность, патогенез, особенности клинических проявлений // Вестник дерматологии и венерологии. 2015. № 3. С. 36–45.

[31] Wang U, Wang B, Huang Y, et al. Multi-transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of rosacea. J Inflammation Res. 2022;(15):2141–2156. doi: 10.2147/JIR.S356551

[32] Wang U., Wang B., Huang Y., et al. Multi-Transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of rosacea // J Inflammation Res. 2022. N 15. Р. 2141–2156. doi: 10.2147/JIR.S356551

[33] Abram K, Silm H, Maaroos HI. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24(5):565–571. doi: 10.1111/j.1468-3083.2009.03472.x

[34] Abram K., Silm H., Maaroos H.I. Risk factors associated with rosacea // J Eur Acad Dermatol Venereol. 2010. Vol. 24, N 5. Р. 565–571. doi: 10.1111/j.1468-3083.2009.03472.x

[35] Svirshchevskaya EV, Matushevskaya EV, Matushevskaya YI. Topical issues of the pathogenesis and treatment of rosacea. Clin Dermatol Venereol. 2017;(4):4–12 (In Russ). doi: 10.17116/klinderma20171644-13

[36] Свирщевская Е.В., Матушевская Е.В., Матушевская Ю.И. Актуальные вопросы патогенеза и терапии розацеа // Клиническая дерматология и венерология. 2017. № 4. С. 4–12. doi: 10.17116/klinderma20171644-13

[37] Yazici AC, Tamer L, Ikizoglu G, et al. GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. J Photodermatol Photoimmunol Photomed. 2006;22:208–210. doi: 10.1111/j.1600-0781.2006.00220.x

[38] Yazici A.C., Tamer L., Ikizoglu G., et al. GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea // J Photodermatol Photoimmunol Photomed. 2006. Vol. 22. Р. 208–210. doi: 10.1111/j.1600-0781.2006.00220.x

[39] Agafonova EV, Kruglova LS, Avagumyn MA. Genetic markers of rosacea. J New Med Technologies. 2018;25(4):137–144. (In Russ). doi: 10.24411/1609-2163-2018-16297

[40] Агафонова Е.В., Круглова Л.С., Авагумян М.А. Генетические маркеры розацеа // Вестник новых медицинских технологий. 2018. Т. 25, № 4. С. 137–144. doi: 10.24411/1609-2163-2018-16297

[41] Hayran Y, Lay I, Mocan MC, et al. Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study. J Am Acad Dermatol. 2019;81(2):348–354. doi: 10.1016/j.jaad.2019.03.055

[42] Hayran Y., Lay I., Mocan M.C., et al. Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study // J Am Acad Dermatol. 2019. Vol. 81, N 2. P. 348–354. doi: 10.1016/j.jaad.2019.03.055

[43] Aponte JL, Chiano NM, Yerges-Armstrong LM, et al. Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. Human Molecular Genetics. 2018;2(15):2762–2772. doi: 10.1093/hmg/ddy184

[44] Aponte J.L., Chiano N.M., Yerges-Armstrong L.M., et al. Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes // Human Molecular Genetics. 2018. Vol. 27, N 15. Р. 2762–2772. doi: 10.1093/hmg/ddy184

[45] Park BW, Ha JM, Cho EB, et al. A study on vitamin D and cathelicidin status in patients with rosacea: Serum level and tissue expression. Ann Dermatol. 2018;30(2):136–142. doi: 10.5021/ad.2018.30.2.136

[46] Park B.W., Ha J.M., Cho E.B., et al. A study on vitamin D and cathelicidin status in patients with rosacea: Serum level and tissue expression // Ann Dermatol. 2018. Vol. 30, N 2. Р. 136–142. doi: 10.5021/ad.2018.30.2.136

[47] Davydova AM, Bakulev AL, Morrison AM, Leonova MA. Molecular mechanisms of rosacea pathogenesis. Saratov State Med University J. 2013;9(3):561–565. (In Russ).

[48] Давыдова А.В., Бакулев А.Л., Моррисон А.В., Леонова М.А. Молекулярные механизмы патогенеза розацеа (обзор) // Саратовский научно-медицинский журнал. 2013. Т. 9, № 3. C. 561–565.

[49] Wang L, Cheng B, Ju Q, Sun BK. AhR regulates peptidoglycan-induced inflammatory gene expression in human keratinocytes. J Innat Immun. 2022;14(2):124–134. doi: 10.1159/000517627

[50] Wang L., Cheng B., Ju Q., Sun B.K. AhR regulates peptidoglycan-induced inflammatory gene expression in human keratinocytes // J Innat Immun. 2022. Vol. 14, N 2. Р. 124–134. doi: 10.1159/000517627

[51] Deng Z, Chen M, Liu Y, et al. A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea. EMBO Mol Med. 2021;13(5):e13560. doi: 10.15252/emmm.202013560

[52] Deng Z., Chen M., Liu Y., et al. A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea // EMBO Mol Med. 2021. Vol. 13, N 5. Р. e13560. doi: 10.15252/emmm.202013560

[53] Peng Q, Sha K, Liu Y, et al. mTORC1-Mediated angiogenesis is required for the development of rosacea. Front Cell Dev Biol. 2021;(9):751–785. doi: 10.3389/fcell.2021.751785

[54] Peng Q., Sha K., Liu Y., et al. mTORC1-Mediated angiogenesis is required for the development of rosacea // Front Cell Dev Biol. 2021. N 9. Р. 751–785. doi: 10.3389/fcell.2021.751785

[55] Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018;40(3):249–259. doi: 10.1007/s00281-018-0675-z

[56] Choi J.E., Di Nardo A. Skin neurogenic inflammation // Semin Immunopathol. 2018. Vol. 40, N 3. Р. 249–259. doi: 10.1007/s00281-018-0675-z

[57] Shih YH, Xu J, Kumar A, et al. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis. J Investigative Dermatol. 2020;140(5):1100–1103.e4. doi: 10.1016/j.jid.2019.09.021

[58] Shih Y.H., Xu J., Kumar A., et al. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis // J Investigative Dermatol. 2020. Vol. 140, N 5. Р. 1100–1103.e4. doi: 10.1016/j.jid.2019.09.021

[59] Mueller SN. Neural control of immune cell trafficking. J Exp Med. 2022;219(3):e20211604. doi: 10.1084/jem.202116041

[60] Mueller S.N. Neural control of immune cell trafficking // J Exp Med. 2022. Vol. 219, N 3. Р. e20211604. doi: 10.1084/jem.202116041

[61] Olisova OY, Anpilogova EM. Current management options for rosacea: Clear skin is our reality. Russ J Skin Venereal Dis. 2020;23(5):324–333. (In Russ). doi: 10.17816/dv49867

[62] Олисова О.Ю., Анпилогова Е.М. Лечение розацеа сегодня: достижение полностью чистой кожи ― наша реальность // Российский журнал кожных и венерических болезней. 2020. Т. 23, № 5. С. 324–333. doi: 10.17816/dv49867

[63] Rusina TS, Snarskaya ES. Еrythematotelangiectatic rosacea: The optimization of diagnostics and therapy. Russ J Skin Venereal Dis. 2019;22(3-4):111–119. (In Russ).

[64] Русина Т.С., Снарская Е.С. Эритематозно-телеангиэктатический тип розацеа: оптимизация диагностики и разработка комплексной терапии // Российский журнал кожных и венерических болезней. 2019. Т. 22, № 3-4. С. 111–119.

[65] Romashkina AS, Olisova OY, Snarskaya ES. Transdermal redermalization in rosacea: Rehab procedures in intercurrent period. Russ J Skin Venereal Dis. 2020;23(3):182–187. (In Russ). doi: 10.17816/dv48901

[66] Ромашкина А.С., Олисова О.Ю., Снарская Е.С. Трансдермальная редермализация при розацеа: процедуры REHAB в межрецидивный период // Российский журнал кожных и венерических болезней. 2020. Т. 23, № 3. С. 182–187. doi: 10.17816/dv48901

[67] Capec P, Dicherson TJ. Sensing the deadliest toxin: Technologist for botulinum neurotoxin. Toxins (Basel). 2010;2(1):24–53. doi: 10.3390/toxins2010024

[68] Capec P., Dicherson T.J. Sensing the deadliest toxin: Technologist for botulinum neurotoxin // Toxins (Basel). 2010. Vol. 2, N 1. Р. 24–53. doi: 10.3390/toxins2010024

[69] Scala J, Vojvodic A, Vojovodic P, et al. Botulin toxin use in rosacea and facial flushing treatment. Open Access Maced J Med Sci. 2019;7(18):2985–2987. doi: 10.3889/oamjms.2019.784

[70] Scala J., Vojvodic A., Vojovodic P., et al. Botulin toxin use in rosacea and facial flushing treatment // Open Access Maced J Med Sci. 2019. Vol. 7, N 18. Р. 2985–2987. doi: 10.3889/oamjms.2019.784

[71] Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574. doi: 10.1080/19381980.2017.1361574

[72] Rainer B.M., Kang S., Chien A.L. Rosacea: Epidemiology, pathogenesis, and treatment // Dermatoendocrinol. 2017. Vol. 9, N 1. Р. e1361574. doi: 10.1080/19381980.2017.1361574

[73] Field M, Splevins A, Picaut P, et al. Abobotulinumtoxin A (Dysport), Onabotulinumtoxin A (Botox), and Incobotulinumtoxin A (Xeomin) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel). 2018;10(12):535. doi: 10.3390/toxins10120535

[74] Field M., Splevins A., Picaut P., et al. Abobotulinumtoxin A (Dysport), Onabotulinumtoxin A (Botox), and Incobotulinumtoxin A (Xeomin) neurotoxin content and potential implications for duration of response in patients // Toxins (Basel). 2018. Vol. 10, N 12. Р. 535. doi: 10.3390/toxins10120535

[75] Artemenko AR, Dutikova EM, Zabnenkova OV, et al. The ABC of botulinum therapy: A scientific and practical publication. Ed. by S.L. Timerbayeva. Moscow: Practical Medicine; 2018. 416 p. (In Russ).

[76] Артеменко А.Р., Дутикова Е.М., Забненкова О.В., и др. Азбука ботулинотерапии: научно-практическое издание / под ред. С.Л. Тимербаевой. Москва: Практическая медицина, 2018. 416 с.

[77] Calvisi L, Diaspro A, Sito G. Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. J Cosmet Dermatol. 2022;21(9):3747–3753. doi: 10.1111/jocd.14692

[78] Calvisi L., Diaspro A., Sito G. Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea // J Cosmet Dermatol. 2022. Vol. 21, N 9. Р. 3747–3753. doi: 10.1111/jocd.14692

[79] Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. PAIN. 2010;149(2):316–324. doi: 10.1016/j.pain.2010.02.024

[80] Carmichael N.M., Dostrovsky J.O., Charlton M.P. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin // PAIN. 2010. Vol. 149, N 2. Р. 316–324. doi: 10.1016/j.pain.2010.02.024

[81] Eun J, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58–64. doi: 10.1016/j.jdermsci.2018.12.004

[82] Eun J., Werbel T., Wang Z., et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation // J Dermatol Sci. 2019. Vol. 93, N 1. Р. 58–64. doi: 10.1016/j.jdermsci.2018.12.004

[83] Dayan SH, Ashourian N, Cho K. A pilot, double-blind. Placebo-controlled study to assess the efficacy and safety of incobotulinumtoxin A injections in the treatment of rosacea. J Drugs Dermatol. 2017;16(6):549–554.

[84] Dayan S.H., Ashourian N., Cho K. A pilot, double-blind. placebo-controlled study to assess the efficacy and safety of incobotulinumtoxin a injections in the treatment of rosacea // J Drugs Dermatol 2017. Vol. 16, N 6. Р. 549–554.

[85] Odo ME, Odo LM, Farias RV, et al. Botulinum toxin for the treatment of menopausal hot flushes: A pilot study. Dermatol Surg. 2011;37(11):1579–1583. doi: 10.1111/j.1524-4725.2011.02109.x

[86] Odo M.E., Odo L.M., Farias R.V., et al. Botulinum toxin for the treatment of menopausal hot flushes: A pilot study // Dermatol Surg 2011. Vol. 37, N 11. Р. 1579–1583. doi: 10.1111/j.1524-4725.2011.02109.x

[87] Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxin A on facial erythema of rosacea. Dermatol Surg. 2015;4(Suppl 1):S9–16. doi: 10.1097/DSS.0000000000000277

[88] Bloom B.S., Payongayong L., Mourin A., Goldberg D.J. Impact of intradermal abobotulinumtoxin A on facial erythema of rosacea // Dermatol Surg. 2015. Vol. 41, Suppl. 1. Р. S9–16. doi: 10.1097/DSS.0000000000000277

[89] Bharti J, Sonthalia S, Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea J Am Acad Dermatol. 2018;S0190–9622(18)30808-30809. doi: 10.1016/j.jaad.2018.05.014

[90] Bharti J., Sonthalia S., Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea // J Am Acad Dermatol. 2018. Vol. S0190-9622(18)30808-9. Р. 30808–30809. doi: 10.1016/j.jaad.2018.05.014

[91] Friedman O, Koren A, Niv R, et al. The toxic edge-A novel treatment for refreactoryerythema and flushing of rosacea. Lasers Surg Med. 2019;51(4):325–331. doi: 10.1002/lsm.23023

[92] Friedman O., Koren A., Niv R., et al. The toxic edge-A novel treatment for refreactory erythema and flushing of rosacea // Lasers Surg Med. 2019. Vol. 51, N 4. Р. 325–331. doi: 10.1002/lsm.23023

[93] Schlessinger J, Gilbert E, Cohen JL, Kaufman J. New Uses of abobotulinumtoxin A in aesthetics. Aesthet Surg J. 2017;37(Suppl 1):S45–S58. doi: 10.1093/asj/sjx005

[94] Schlessinger J., Gilbert E., Cohen J.L., Kaufman J. New uses of abobotulinumtoxin A in aesthetics // Aesthet Surg J. 2017. Vol. 37, Suppl. 1. Р. S45–S58. doi: 10.1093/asj/sjx005

[95] Tong Y, Luo W, Gao Y, et al. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea. Dermatol Ther. 2022;35(5):e15395. doi: 10.1111/dth.15395

[96] Tong Y., Luo W., Gao Y., et al. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea // Dermatol Ther. 2022. Vol. 35, N 5. Р. e15395. doi: 10.1111/dth.15395

[97] Egorova OA. Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea. Medical Alphabet. 2019;2(26):100–104. (In Russ). doi: 10.33667/2078-5631-2019-2-26(401)-100-104

[98] Егорова О.А. Применение ботулинического токсина типа А у пациентов с эритематозно-телеангиэктатическим подтипом розацеа // Медицинский алфавит. 2019. Т. 2, № 26. С. 100–104. doi: 10.33667/2078-5631-2019-2-26(401)-100-104

[99] Verbovaya ED, Rodina AL. Botulinum therapy in treatment of patients with rosacea. Medical Alphabet. 2022;(8):103–106. (In Russ). doi: 10.33667/2078-5631-2022-8-103-106

[100] Вербовая Е.Д., Родина А.Л. Ботулинотерапия в лечении больных розацеа // Медицинский алфавит. 2022. № 8. С. 103–106. doi: 10.33667/2078-5631-2022-8-103-106

RIGHTS & PERMISSIONS

Yakovleva A.O., Verbenko D.A., Kondrakhina I.N., Plakhova K.I., Kubanov A.A.